Small molecules for combating multidrug-resistant superbug Candida auris infections

作     者：Jie Tu Na Liu Yahui Huang Wanzhen Yang Chunquan Sheng Jie Tu;Na Liu;Yahui Huang;Wanzhen Yang;Chunquan Sheng

作者机构：School of PharmacySecond Military Medical UniversityShanghai 200433China 

出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)

年 卷 期：2022年第12卷第11期

页      面：4056-4074页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 100701[医学-药物化学] 10[医学] 

基　　金：supported by the National Natural Science Foundation (81725020, 82003591 and 81973175, China) the Innovation Program of Shanghai Municipal Education Commission(2019-01-07-00-07-E00073, China) Science and Technology Commission of Shanghai Municipality (20S11900400, China) 

主　　题：Candidaauris Antifungal agents Drug resistance Virulence factors Antifungal targets 

摘      要：Candida auris is emerging as a major global threat to human health. C. auris infections are associated with high mortality due to intrinsic multi-drug resistance. Currently, therapeutic options for the treatment of C. auris infections are rather limited. We aim to provide a comprehensive review of current strategies, drug candidates, and lead compounds in the discovery and development of novel therapeutic agents against C. auris. The drug resistance profiles and mechanisms are briefly summarized. The structures and activities of clinical candidates, drug combinations, antifungal chemosensitizers, repositioned drugs, new targets, and new types of compounds will be illustrated in detail, and perspectives for guiding future research will be provided. We hope that this review will be helpful to prompting the drug development process to combat this fungal pathogen.